Inclusion Criteria:

          -  Confirmed no evidence of cancer on computed tomography (CT) scan within 6 months prior
             to starting treatment

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

          -  Patients must have platelets >= 100 x 10^9/L

          -  Participants of child-bearing potential must agree to use adequate contraceptive
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study
             entry

               -  Should a woman become pregnant or suspect she is pregnant while she or her
                  partner is participating in this study, she should inform her treating physician
                  immediately

          -  Participant must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure

          -  PATIENTS AT HIGH-RISK FOR LUNG CANCER COHORT ONLY (COHORT A)

          -  Must have documented at least one risk factor for lung cancer which includes:

               -  Moderate to severe chronic obstructive pulmonary disease (COPD) defined as
                  FEV1/FVC ratio <=75%

               -  Positive family history of lung cancer defined as a first degree relative

               -  Low body mass index (BMI)

               -  History of pneumonia within the last 5 years prior to enrollment

               -  Occupational exposure such as asbestos, radon and any other that investigator
                  would deem high risk

          -  Must have quit smoking =< ten years ago or be a current smoker

          -  Must have at least 50 pack year smoking history

          -  Must have documented pulmonary function test within the last 3 years prior to
             enrollment. If a patient cannot tolerate a pulmonary function test, an incentive
             spirometry will be acceptable in place of a pulmonary function test

          -  LUNG CANCER SURVIVOR COHORT ONLY (COHORT B)

          -  Completion of adjuvant therapy after surgery at least 3 months prior to enrollment for
             lung cancer

          -  Confirmed non-small cell lung cancer (NSCLC) stage IB through 3A at initial diagnosis

        Exclusion Criteria:

          -  Clinically inappropriate to have a bronchoscopy procedure

          -  Known uncontrolled intercurrent illness including, but not limited to, ongoing or
             active infection, symptomatic congestive heart failure, unstable angina pectoris,
             history of clinically significant cardiac arrhythmia, or psychiatric illness/social
             situations that would limit compliance with study requirements

          -  Pregnant or nursing female participants

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug

          -  Received an investigational agent within 30 days prior to enrollment

          -  Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired
             immunodeficiency syndrome [AIDS] or other immune depressing disease). Testing is not
             mandatory

          -  Patient has known hypersensitivity to the components of the study drugs or any analogs

          -  History of autoimmune disorder, with exception of patients with vitiligo or
             endocrine-related autoimmune conditions receiving appropriate hormonal supplementation
             who are eligible. Systemic use of immunosuppressant drugs such as steroids (except as
             hormone replacement therapy or short-course supportive medication such as chemotherapy
             or drug allergy, etc.), azathioprine, tacrolimus, cyclosporine, etc. within 4 weeks
             before recruitment